Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance

European Journal of Cancer

Volumn 47, Issue 8, 2011, Pages 1231-1243

  Krumbach, Rebekka ^a   Schüler, Julia ^a   Hofmann, Michael ^a   Giesemann, Torsten ^a   Fiebig, Heinz Herbert ^a   Beckers, Thomas ^a  

^a CHARLES RIVER LABORATORIES   (United States)

Author keywords

Cetuximab; EGFR; MET; Patient derived xenografts; Primary drug resistance

Indexed keywords

AMPHIREGULIN; B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIREGULIN; K RAS PROTEIN; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CELL MIGRATION; CONTROLLED STUDY; DRUG MECHANISM; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE TYPES; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MICE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3;

EID: 79955525586     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.12.019     Document Type: Article

References (48)

1. E.M. Bublil, and Y. Yarden The EGF receptor family: spearheading a merger of signaling and therapeutics Curr Opin Cell Biol 19 2 2007 124 134 (Pubitemid 46386405)
2. F. Rivera, M.E. Vega-Villegas, and M.F. Lopez-Brea Cetuximab, its clinical use and future perspectives Anticancer Drugs 19 2 2008 99 113
3. M. Peipp, M. Dechant, and T. Valerius Effector mechanisms of therapeutic antibodies against ErbB receptors Curr Opin Immunol 20 4 2008 436 443
4. S. Li, K.R. Schmitz, and P.D. Jeffrey Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 4 2005 301 311 (Pubitemid 40544648)
5. M.L. Janmaat, F.A. Kruyt, J.A. Rodriguez, and G. Giaccone Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways Clin Cancer Res 9 6 2003 2316 2326 (Pubitemid 36687658)
6. J. Amann, S. Kalyankrishna, and P.P. Massion Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer Cancer Res 65 1 2005 226 235 (Pubitemid 40070814)
7. F. Bibeau, E. Lopez-Crapez, and F. Di Fiore Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 7 2009 1122 1129
8. Z. Weihua, R. Tsan, and W.C. Huang Survival of cancer cells is maintained by EGFR independent of its kinase activity Cancer Cell 13 5 2008 385 393 (Pubitemid 351609444)
9. N. Moosmann, and V. Heinemann Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer Expert Rev Anticancer Ther 8 3 2008 319 329 (Pubitemid 351836281)
10. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345 (Pubitemid 38944402)
11. F. Di Nicolantonio, M. Martini, and F. Molinari Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer J Clin Oncol 26 35 2008 5705 5712
12. S. Khambata-Ford, C.R. Garrett, and N.J. Meropol Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 22 2007 3230 3237 (Pubitemid 47325606)
13. W. De Roock, B. Claes, and D. Bernasconi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis Lancet Oncol 11 8 2010 753 762
14. V. Heinemann, S. Stintzing, T. Kirchner, S. Boeck, and A. Jung Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treat Rev 35 3 2009 262 271
15. D.L. Wheeler, S. Huang, and T.J. Kruser Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members Oncogene 27 28 2008 3944 3956 (Pubitemid 351913636)
16. Y. Lu, X. Li, and K. Liang Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab Cancer Res 67 17 2007 8240 8247 (Pubitemid 47395161)
17. D.L. Wheeler, M. Iida, and T.J. Kruser Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab Cancer Biol Ther 8 8 2009 696 703
18. W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 3 2005 e73
19. S. Kobayashi, T.J. Boggon, and T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 8 2005 786 792 (Pubitemid 40271173)
20. P. Stephens, C. Hunter, and G. Bignell Lung cancer: intragenic ERBB2 kinase mutations in tumours Nature 431 7008 2004 525 526
21. S.E. Wang, A. Narasanna, and M. Perez-Torres HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors Cancer Cell 10 1 2006 25 38
22. F. Morgillo, W.Y. Kim, and E.S. Kim Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib Clin Cancer Res 13 9 2007 2795 2803 (Pubitemid 46788049)
23. F. Morgillo, and H.Y. Lee Resistance to epidermal growth factor receptor-targeted therapy Drug Resist Updat 8 5 2005 298 310 (Pubitemid 41677713)
24. M. Guix, A.C. Faber, and S.E. Wang Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins J Clin Invest 118 7 2008 2609 2619 (Pubitemid 351949788)
25. C. Birchmeier, W. Birchmeier, E. Gherardi, and G.F. Vande Woude Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 12 2003 915 925 (Pubitemid 37493640)
26. J.A. Engelman, K. Zejnullahu, and T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 5827 2007 1039 1043 (Pubitemid 46799492)
27. T. Onitsuka, H. Uramoto, and N. Nose Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status Lung Cancer 7 30 2009 2513 2517
28. S. Agarwal, C. Zerillo, and J. Kolmakova Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells Br J Cancer 100 6 2009 941 949
29. P.A. Zucali, M.G. Ruiz, and E. Giovannetti Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann Oncol 19 9 2008 1605 1612
30. H. Fiebig, W. Dengler, and T. Roth Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents H.H.Bde Fiebig, Relevance of tumor models for anticancer drug development 1999 Karger Basel 29 50
31. B. Liu, M. Fang, and M. Schmidt Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity Br J Cancer 82 12 2000 1991 1999 (Pubitemid 30326461)
32. H.H. Fiebig, A. Maier, and A.M. Burger Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery Eur J Cancer 40 6 2004 802 820 (Pubitemid 38519759)
33. A. Guo, J. Villen, and J. Kornhauser Signaling networks assembled by oncogenic EGFR and c-Met Proc Natl Acad Sci USA 105 2 2008 692 697 (Pubitemid 351171770)
34. P. Soubeyran, K. Kowanetz, I. Szymkiewicz, W.Y. Langdon, and I. Dikic Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors Nature 416 6877 2002 183 187 (Pubitemid 34246476)
35. M.S. Brose, P. Volpe, and M. Feldman BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 23 2002 6997 7000 (Pubitemid 35424092)
36. C.H. Yeang, F. McCormick, and A. Levine Combinatorial patterns of somatic gene mutations in cancer FASEB J 22 8 2008 2605 2622
37. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, and A. Bardelli Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 19 2009 1308 1324
38. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 1757 1765
39. A. Sartore-Bianchi, F. Di Nicolantonio, and M. Nichelatti Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer PLoS One 4 10 2009 e7287
40. W. De Roock, D.J. Jonker, and F. Di Nicolantonio Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 16 2010 1812 1820
41. R. Bianco, S. Garofalo, and R. Rosa Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs Br J Cancer 98 5 2008 923 930 (Pubitemid 351341618)
42. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 5 2005 341 354 (Pubitemid 40637826)
43. K. Kawaguchi, H. Murakami, and T. Taniguchi Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells Carcinogenesis 30 7 2009 1097 1105
44. N. Puri, and R. Salgia Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer J Carcinog 7 2008 9
45. S. Yano, W. Wang, and Q. Li Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 22 2008 9479 9487
46. L.V. Sequist, W.L. Akerley, and W. Brugger Final results from ARQ 197-209: a global randomized placebo-controlled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naive patinets with advanced non-small cell lung cancer (NSCLC) Ann Oncol 21 Suppl. 8 2010 viii 122
47. D. Spigel, T. Ervin, and R. Ramlau Randomized multicenter double-blind placebo-controlled phase II study evaluating MetMAb, an antibody to MET receptor, in combination with erlotinib, in patients with advanced non-small cell lung cancer Ann Oncol 21 Suppl. 8 2010 viii
48. F. Cappuzzo, M. Varella-Garcia, and G. Finocchiaro Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients Br J Cancer 99 1 2008 83 89 (Pubitemid 351920237)